Search filters

Filters
Clear All

Phase

  • 67
  • 68
  • 1
  • 81
  • 60
  • 13
  • 191
  • 557
  • 217
  • 9
  • 22
  • 529
  • 557
  • 3

Found 560 Barrett's Esophagus trials

A listing of Barrett's Esophagus medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

18 years - 99 years
All genders
Phase 2
Interventional
The purpose of this study is to see if the Study drug works in the prevention of cytokine release syndrome. This is an open-label study, which means that both the participant and the study Doctor will know what study drug the participant is receiving. Participants will be in the study …
99 years or below
All genders
This patisiran expanded access protocol (EAP) is an open-label, multicenter, single-arm study designed to provide pre-approval access to investigational patisiran for patients with ATTR amyloidosis with cardiomyopathy who, at baseline, have an inadequate response to or cannot tolerate standard of care. An intravenous infusion of study drug (patisiran 0.3 mg/kg) …
18 years - 65 years
All genders
The purpose of this study is to test, in surgery patients and controls aged 18 to 65, whether measurable abnormalities found in pre-surgical MRI can predict surgical outcomes in epilepsy, to improve the understanding for the causes of surgical failure, and to pave the way for future use of neuroimaging …
99 years or below
All genders
Using a pilot cohort, we hope to estimate tac PK parameters and conduct simulation studies to support design of a multicenter study to develop and validate a robust post-lung transplant tac population pharmacokinetic (popPK) model. The primary outcome will be the area under the concentration-time curve (AUC), which will provide …
99 years or below
All genders
Phase 1
First-in-human, Phase 1b/2 safety study of the antibody-drug conjugate (ADC) XMT-1536 administered as an IV infusion once every four weeks. Patients with tumor types likely to express NaPi2b were enrolled in dose escalation. Patients with platinum-resistant ovarian cancer and non-small cell lung cancer (adenocarcinoma subtype) are being enrolled in the …
99 years or below
All genders
Phase 1
This study tests the effects of an investigational product, CT-0508, and to see how safe CT-0508 is for patients with advanced cancer. One purpose of this study is to see if CT-0508 cells can be made and then safely given back to patients with HER2-positive cancers. A second purpose is …
 A Study to Evaluate the Effectiveness and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis
18 years - 99 years
All genders
Phase 3
Interventional
AL (or light chain) amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down. These free light chains bind together to form amyloid fibrils that build up in the extracellular space of organs, affecting the kidneys, heart, liver, spleen, nervous …
18 years - 99 years
All genders
Phase 2
Interventional
The research study is being conducted to test the safety and efficacy of SGX301 (an investigational drug) in patients with mycosis fungoides in combination with light therapy using standard fluorescent lights. Eligible participants must have been diagnosed with mycosis fungoides, a form of Cutaneous T-cell Lymphoma. Participants will be asked …
99 years or below
All genders
This open-label, single arm clinical study is being conducted to assess the long-term safety and efficacy of aducanumab in participants with Alzheimer's disease who were actively participating in Aducanumab clinical studies 103, 205, 301, or 302 (aducanumab feeder studies) as of March 21st 2019. Participants who participated in 221AD302 will …
99 years or below
All genders
This is a multi-center, randomized, double-blind, placebo-controlled study of safety and efficacy of ISIS 678354 in patients with FCS. Eligible patients will enter an approximately 4-week Screening Period and an approximately 2-week qualification period. Approximately 60 eligible patients will be randomized 1:1 to Cohort A (50 mg) or Cohort B …
211 - 220 of 560